RecruitingNCT07382752

Decoupling Immunotherapy Toxicity and Cancer Response

Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity

Sponsor

M.D. Anderson Cancer Center

Enrollment

1,200 participants

Start Date

Jan 9, 2026

Study Type

OBSERVATIONAL

Conditions

Tumor Cardiovascular

Summary

This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Age ≥ 18 years
Plan to start immune checkpoint inhibitor for cancer therapy

Exclusion Criteria2

No baseline blood collection prior to initiation
At time of evaluation not determined to be a good candidate for evaluation of outcome events by the principal investigator

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.